Short Interest in NPS Pharmaceuticals Drops By 8.6% (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) was the recipient of a significant decrease in short interest in May. As of May 30th, there was short interest totalling 10,867,727 shares, a decrease of 8.6% from the May 15th total of 11,896,553 shares, ARN reports. Currently, 11.1% of the shares of the company are short sold. Based on an average daily volume of 2,704,955 shares, the days-to-cover ratio is currently 4.0 days.
NPSP has been the subject of a number of recent research reports. Analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Tuesday, May 13th. They now have a $33.00 price target on the stock. Finally, analysts at Leerink Swann reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Friday, May 9th. They now have a $40.00 price target on the stock, down previously from $47.00. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. NPS Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $38.80.
NPS Pharmaceuticals (NASDAQ:NPSP) opened at 33.10 on Wednesday. NPS Pharmaceuticals has a 52 week low of $14.06 and a 52 week high of $39.68. The stock has a 50-day moving average of $29.39 and a 200-day moving average of $30.71. The company’s market cap is $3.519 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The company had revenue of $44.04 million for the quarter, compared to the consensus estimate of $48.30 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 73.2% on a year-over-year basis. On average, analysts predict that NPS Pharmaceuticals will post $0.04 earnings per share for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.